세계의 HIV 진단 시장 예측(-2030년) : 검사 유형별, 제품별, 최종사용자별, 지역별

The global HIV diagnostics market is projected to reach USD 5.31 Billion by 2030 from USD 3.25 Billion in 2025, at a CAGR of 10.3% during the forecast period.

The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent.

Government-led health initiatives and widespread public awareness campaigns encouraging early HIV testing are key drivers of market growth. Additionally, continuous advancements in rapid testing technologies, along with the increasing availability and affordability of self-testing kits, are improving patient compliance and boosting adoption rates. The expansion of diagnostic laboratories, integration of artificial intelligence in diagnostics, and growing collaborations between healthcare organizations and private entities further contribute to market expansion.

However, certain challenges may hinder growth, including the high cost of diagnostic tests, limited access to healthcare in remote regions, and a shortage of skilled professionals to conduct and interpret tests. Regulatory hurdles and concerns regarding the accuracy and reliability of some testing methods also pose potential barriers.

Despite these challenges, the HIV diagnostics market is expected to experience steady growth, driven by increasing awareness, improved healthcare infrastructure, rising government funding for HIV screening programs, and the growing demand for fast, convenient, and highly accurate testing solutions. The increasing focus on early detection and timely intervention, combined with technological innovations in point-of-care testing, is likely to create significant opportunities for market players in the coming years. "The consumables segment accounted for the largest share of the market in 2024, by product."

The HIV diagnostics market is classified by product type into consumables, instruments, and software & services. In 2024, the consumables segment dominated the market, driven by the recurring demand from laboratories and hospitals, the rising prevalence of HIV/AIDS, and government initiatives supporting the development of advanced consumables.

"The confirmatory tests segment accounted for the largest share of the market in 2024, by test type."

By test type, the market is segmented into screening tests, confirmatory tests, and monitoring tests. The monitoring tests segment held the largest share in 2024 and is expected to grow at the highest CAGR. This growth is fueled by increasing awareness of HIV testing, a high volume of monitoring test samples, and the expansion of diagnostic laboratories specializing in HIV/AIDS testing. Additionally, advancements in monitoring test kits are further accelerating the segment's expansion.

"Diagnostic Laboratories segment dominated the HIV diagnostics market in 2024, based on end user."

The HIV diagnostics market is segmented by end users into diagnostic laboratories, hospitals, blood banks, home care settings, and others. In 2024, diagnostic laboratories accounted for the largest market share, driven by the increasing prevalence of HIV/AIDS, the expansion of diagnostic facilities, the rising demand for sample testing, and advancements in point-of-care (POC) technology.

The HIV diagnostics market is segmented into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2024, North America led the global market, driven by factors such as the rising prevalence of HIV/AIDS, advancements in point-of-care (POC) diagnostic instruments and test kits, growing awareness initiatives, and an increase in blood transfusions and donations. The presence of well-established healthcare infrastructure, significant investments in research and development, and supportive government policies further contributed to the region's market dominance.

However, the Asia Pacific region is projected to experience the highest compound annual growth rate during the forecast period. This rapid expansion is fueled by the rising number of HIV cases, the increasing availability of advanced POC diagnostic products, and growing healthcare investments in emerging economies. Additionally, government-led initiatives promoting HIV awareness, improved healthcare accessibility, and a surge in global market players expanding their presence in the region are further accelerating market growth. The region's increasing focus on early disease detection, combined with technological advancements and growing collaborations between public and private healthcare organizations, is expected to create significant opportunities for market expansion.

The break-up of the profile of primary participants in the HIV diagnostics market:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: M-level - 30%, D-level - 50%, and Others - 20%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Others-4%

The key players in this market are are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others.

Research Coverage:

• This research report categorizes the HIV diagnostics market by device type (consumables, instruments, software & services ), by test type (screening tests, confirmatory tests, monitoring tests and other HIV diagnostic tests), by end user (diagnostic laboratories, blood banks, home care settings, hospitals and other endusers), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the HIV diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the HIV diagnostics market. Competitive analysis of upcoming startups in the HIV diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HIV diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Rising prevalence of HIV/AIDS, Increasing number of blood transfusions & blood donations, Advantages offered by POC diagnostic kits & instruments) opportunities (Growth opportunities in emerging economies), restraints (high cost of NATs), and challenges (lack of skilled workforce) influencing the growth of the HIV diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the HIV diagnostics market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the HIV diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HIV diagnostics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET SHARE ASSUMPTIONS
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HIV DIAGNOSTICS MARKET OVERVIEW
• 4.2 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of HIV/AIDS
    • 5.2.1.2 Increasing number of blood transfusions & blood donations
    • 5.2.1.3 Advantages offered by POC diagnostic kits & instruments
    • 5.2.1.4 Increasing initiatives for HIV awareness campaigns
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of NATs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential of emerging economies
    • 5.2.3.2 Trend of self-testing and growing preference for at- home diagnostic kits
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Operational barriers and shortage of skilled laboratory technicians
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE OF HIV DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021-2023
  • 5.4.3 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS, BY REGION, 2021-2023 (USD)
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 ELISA
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Western blot tests
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 PCR
• 5.9 INVESTMENT & FUNDING SCENARIO
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 3822
  • 5.11.2 EXPORT DATA FOR HS CODE 3822
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 ROLE OF COMMUNITY-BASED ORGANIZATIONS (CBOS) IN SUPPORTING PEOPLE WITH HIV
  • 5.13.2 MANAGING HIGH BLOOD PRESSURE AND BLOOD SUGAR IN HIV-POSITIVE PATIENTS
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14.2 REGULATORY FRAMEWORK
    • 5.14.2.1 North America
      • 5.14.2.1.1 US
      • 5.14.2.1.2 Canada
    • 5.14.2.2 Europe
    • 5.14.2.3 Asia Pacific
      • 5.14.2.3.1 China
      • 5.14.2.3.2 Japan
      • 5.14.2.3.3 India
    • 5.14.2.4 Latin America
      • 5.14.2.4.1 Brazil
      • 5.14.2.4.2 Mexico
    • 5.14.2.5 Middle East
    • 5.14.2.6 Africa
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 THREAT OF NEW ENTRANTS
  • 5.15.2 THREAT OF SUBSTITUTES
  • 5.15.3 BARGAINING POWER OF BUYERS
  • 5.15.4 BARGAINING POWER OF SUPPLIERS
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 KEY BUYING CRITERIA, BY PRODUCT
• 5.17 IMPACT OF AI/GENERATIVE AI ON HIV DIAGNOSTICS MARKET
  • 5.17.1 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS
  • 5.17.2 AI USE CASES
  • 5.17.3 COMPANY IMPLEMENTATION OF AI
  • 5.17.4 FUTURE OF AI/GENERATIVE AI

6 HIV DIAGNOSTICS MARKET, BY TEST TYPE

• 6.1 INTRODUCTION
• 6.2 SCREENING TESTS
  • 6.2.1 RAPID TESTS
    • 6.2.1.1 Provision of quick test results and ability to diagnose HIV antibodies to fuel uptake
  • 6.2.2 ELISA
    • 6.2.2.1 Wide applications across infectious disease diagnostics to drive market
  • 6.2.3 OTHER SCREENING TESTS
• 6.3 CONFIRMATORY TESTS
  • 6.3.1 WESTERN BLOT TESTS
    • 6.3.1.1 Gold standard testing for result validation to drive market
  • 6.3.2 OTHER CONFIRMATORY TESTS
• 6.4 MONITORING TESTS
  • 6.4.1 VIRAL LOAD TESTS
    • 6.4.1.1 Accurate provision of quantitative data on HIV infections to boost demand
  • 6.4.2 CD4 TESTS
    • 6.4.2.1 Ability to number CD4 T lymphocyte cells to support market growth
• 6.5 OTHER HIV DIAGNOSTIC TESTS

7 HIV DIAGNOSTICS MARKET, BY PRODUCT

• 7.1 INTRODUCTION
  • 7.1.1 CONSUMABLES
  • 7.1.2 ASSAY KITS & REAGENTS
    • 7.1.2.1 Recurrent purchase to fuel market
  • 7.1.3 OTHER CONSUMABLES
• 7.2 INSTRUMENTS
  • 7.2.1 RISING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
• 7.3 SOFTWARE & SERVICES
  • 7.3.1 INCREASING DEMAND FOR VALUE-ADDED SERVICES & AUTOMATED SOFTWARE TO SUPPORT MARKET GROWTH

8 HIV DIAGNOSTICS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 DIAGNOSTIC LABORATORIES
  • 8.2.1 HIGH VOLUME OF HIV TESTING SAMPLES TO PROPEL MARKET
• 8.3 HOSPITALS
  • 8.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND FAVORABLE REIMBURSEMENTS TO DRIVE MARKET
• 8.4 BLOOD BANKS
  • 8.4.1 RISING NUMBER OF BLOOD DONATIONS TO BOOST DEMAND
• 8.5 HOME CARE SETTINGS
  • 8.5.1 INCREASING PREFERENCE FOR AT-HOME TESTING KITS TO SUPPORT MARKET GROWTH
• 8.6 OTHER END USERS

9 HIV DIAGNOSTICS MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 High healthcare expenditure to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Increasing number of HIV infections and blood donations to drive market
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Favorable government healthcare policies and reimbursements for HIV testing to drive market
  • 9.3.3 UK
    • 9.3.3.1 Rising government support for HIV awareness campaigns to support market growth
  • 9.3.4 FRANCE
    • 9.3.4.1 High prevalence of HIV/AIDS to boost demand
  • 9.3.5 ITALY
    • 9.3.5.1 Increasing number of blood donors to support market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Rising adoption of NAT technology to propel market
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Rising incidence of infectious diseases & HIV to propel market
  • 9.4.3 JAPAN
    • 9.4.3.1 Growing adoption of advanced HIV screening technologies to drive market
  • 9.4.4 INDIA
    • 9.4.4.1 Government initiatives such as free HIV testing to drive market
  • 9.4.5 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Increasing uptake of technologically advanced blood screening tests to drive market
  • 9.5.3 MEXICO
    • 9.5.3.1 Rising establishment of blood banks to support market growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 RISING NUMBER OF HIV DIAGNOSTICS AND SURGICAL PROCEDURES TO FUEL MARKET
  • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 9.7 GCC COUNTRIES
  • 9.7.1 RISING FOCUS ON HIV TESTING AND IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HIV DIAGNOSTICS MARKET
• 10.3 REVENUE ANALYSIS, 2021-2023
• 10.4 MARKET SHARE ANALYSIS, 2023
  • 10.4.1 RANKING OF KEY MARKET PLAYERS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 End-user footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 10.6.5.1 Detailed list of key startups/SME players
    • 10.6.5.2 Competitive benchmarking of key startups/SMEs
• 10.7 COMPANY VALUATION & FINANCIAL METRICS
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 10.9.2 PRODUCT LAUNCHES & APPROVALS
  • 10.9.3 DEALS
  • 10.9.4 EXPANSIONS
  • 10.9.5 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 ABBOTT
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products/Services offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 SIEMENS HEALTHINEERS
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products/Services offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product/Service launches & approvals
      • 11.1.2.3.2 Deals
      • 11.1.2.3.3 Other developments
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 GRIFOLS, S.A.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products/Services offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 DANAHER CORPORATION
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products/Services offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches & approvals
      • 11.1.4.3.2 Deals
      • 11.1.4.3.3 Expansions
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 THERMO FISHER SCIENTIFIC INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products/Services offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product/Service launches & approvals
      • 11.1.5.3.2 Deals
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 BIO-RAD LABORATORIES, INC.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products/Services offered
      • 11.1.6.2.1 Deals
  • 11.1.7 F. HOFFMANN-LA ROCHE LTD.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products/Services offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches & approvals
      • 11.1.7.3.2 Deals
      • 11.1.7.3.3 Expansions
• 11.2 OTHER PLAYERS
  • 11.2.1 BIOMERIEUX
  • 11.2.2 HOLOGIC, INC.
  • 11.2.3 QIAGEN
  • 11.2.4 BD
  • 11.2.5 TRINITY BIOTECH
  • 11.2.6 ORASURE TECHNOLOGIES, INC.
  • 11.2.7 BIOSYNEX SA
  • 11.2.8 WONDFO
  • 11.2.9 GETEIN BIOTECH, INC.
  • 11.2.10 MERIL LIFE SCIENCES PVT. LTD.
  • 11.2.11 ACCUBIOTECH CO., LTD.
  • 11.2.12 BIOLYTICAL LABORATORIES INC.
  • 11.2.13 BIO LAB DIAGNOSTICS (I) PRIVATE LIMITED
  • 11.2.14 ALPINE BIOMEDICALS PVT LTD.
  • 11.2.15 MOLBIO DIAGNOSTICS PVT. LTD.
  • 11.2.16 FORTRESS DIAGNOSTICS
  • 11.2.17 ADVACARE PHARMA (ACCUQUIK)
  • 11.2.18 ADALTIS S.R.L.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS